These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 23837575)

  • 1. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
    Badinloo M; Esmaeili-Mahani S
    Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
    Shingu T; Yamada K; Hara N; Moritake K; Osago H; Terashima M; Uemura T; Yamasaki T; Tsuchiya M
    Cancer Res; 2003 Jul; 63(14):4044-7. PubMed ID: 12874004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
    McDonald GT; Sullivan R; Paré GC; Graham CH
    Exp Cell Res; 2010 Nov; 316(19):3197-206. PubMed ID: 20736003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
    Xie X; Tang B; Zhou J; Gao Q; Zhang P
    Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C; Liu VW; Chan DW; Yao KM; Ngan HY
    Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
    Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
    Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
    Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
    Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
    Krystal GW; Sulanke G; Litz J
    Mol Cancer Ther; 2002 Sep; 1(11):913-22. PubMed ID: 12481412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
    Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
    Urol Int; 2011; 86(3):346-54. PubMed ID: 21273759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
    Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
    Urol Int; 2011; 87(1):105-13. PubMed ID: 21597260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death.
    Zhu L; Derijard B; Chakrabandhu K; Wang BS; Chen HZ; Hueber AO
    Cancer Lett; 2014 Nov; 354(2):355-64. PubMed ID: 25199763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.
    Beurel E; Kornprobst M; Blivet-Van Eggelpoël MJ; Cadoret A; Capeau J; Desbois-Mouthon C
    Int J Oncol; 2005 Jul; 27(1):215-22. PubMed ID: 15942663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway.
    Poh TW; Pervaiz S
    Cancer Res; 2005 Jul; 65(14):6264-74. PubMed ID: 16024628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
    Clark AS; West K; Streicher S; Dennis PA
    Mol Cancer Ther; 2002 Jul; 1(9):707-17. PubMed ID: 12479367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
    Zhou C; Qiu L; Sun Y; Healey S; Wanebo H; Kouttab N; Di W; Yan B; Wan Y
    Int J Oncol; 2006 Jul; 29(1):269-78. PubMed ID: 16773209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death.
    Yu HG; Ai YW; Yu LL; Zhou XD; Liu J; Li JH; Xu XM; Liu S; Chen J; Liu F; Qi YL; Deng Q; Cao J; Liu SQ; Luo HS; Yu JP
    Int J Cancer; 2008 Jan; 122(2):433-43. PubMed ID: 17935137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
    Nguyen DM; Chen GA; Reddy R; Tsai W; Schrump WD; Cole G; Schrump DS
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):365-75. PubMed ID: 14762343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.